Boehringer Ingelheim Pays $730 Million for Hanmi Cancer Drug

Boehringer Ingelheim will pay $50 million upfront and as much as $680 million in milestones for exclusive rights to a novel lung cancer treatment developed by Korea's Hanmi Pharma. BI will have global rights (except South Korea, China and Hong Kong) to HM61713, a novel 3rd generation EGFR targeted therapy. BI also agreed to pay tiered double-digit royalties on all sales revenues. Presumably, Hanmi, which has a strong presence in China, plans to market the drug in China itself. It was the second blockbuster out-licensing deal for Hanmi this year More details.... Share this with colleagues: // //